Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.86 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.86 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.86 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.86 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.86 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.86 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.86 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.86 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.86 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.86 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | NAMPT | P43490 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacinostat SCHEMBL29351399 | 0.92 | HDAC1 (1.00) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| Dacinostat SCHEMBL95240 | 0.92 | HDAC1 (1.00) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| Dacinostat SCHEMBL181782 | 0.92 | HDAC1 (1.00) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL23318496 | 0.90 | HDAC1 (0.81) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL25726601 | 0.90 | HDAC1 (0.71) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL12447343 | 0.90 | HDAC1 (0.84) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL19242460 | 0.89 | HDAC1 (0.80) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL12660519 | 0.89 | HDAC1 (0.79) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL23318495 | 0.88 | HDAC1 (0.79) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL13949830 | 0.88 | HDAC1 (0.92) | HDAC1HDAC3HDAC8HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572854-B2 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| US-8999289-B2 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-04-07 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | HDAC1 2700/4885HDAC3 4021/4885HDAC8 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.